News
SNGXW
0.0090
0.00%
0.0000
Soligenix says HyBryte beats Valchlor in small cutaneous T-cell lymphoma study
Reuters · 21h ago
Soligenix FY25 net loss widens 34% to $11.1 million; revenue drops to no revenue
Reuters · 2d ago
SOLIGENIX ANNOUNCES RECENT ACCOMPLISHMENTS AND YEAR END 2025 FINANCIAL RESULTS
Reuters · 2d ago
Soligenix publishes corporate presentation; pipeline targets rare diseases with ~$2 billion in potential global annual sales
Reuters · 03/26 19:57
Soligenix shares rise; European Commission grants orphan drug designation for SGX945 in Behçet's disease
Reuters · 03/26 11:31
SOLIGENIX RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN COMMISSION FOR SGX945 FOR THE TREATMENT OF BEHÇET'S DISEASE
Reuters · 03/26 11:30
Soligenix to present Phase 2 real-world HyBryte study results for early-stage CTCL at USCLC Workshop 2026
Reuters · 03/23 11:30
HYBRYTE™ TREATMENT RESULTS TO BE PRESENTED AT US CUTANEOUS LYMPHOMA CONSORTIUM ANNUAL WORKSHOP 2026
Reuters · 03/23 11:30
Soligenix CEO Christopher Schaber Discusses Phase 3 HyBryte Interim Analysis Timeline in Podcast Interview
Reuters · 03/19 12:03
Soligenix reports HyBryte CTCL clinical trial summary published in Expert Opinion on Investigational Drugs
Reuters · 03/19 11:33
Soligenix reports HyBryte clinical trial summary publication for early-stage CTCL in Expert Opinion on Investigational Drugs
Reuters · 03/19 11:31
Soligenix SGX945 wins UK MHRA Promising Innovative Medicine designation for Behçet’s disease
Reuters · 03/10 11:54
SOLIGENIX ANNOUNCES SGX945 RECEIVES PROMISING INNOVATIVE MEDICINE DESIGNATION FROM THE UK MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY
Reuters · 03/10 11:31
SOLIGENIX INC - EMA ORPHAN DRUG DESIGNATION PROVIDES 10-YEAR MARKETING EXCLUSIVITY
Reuters · 02/26 12:33
EMA issues positive orphan drug opinion for Soligenix SGX945 in Behçet's disease
Reuters · 02/26 12:32
Soligenix to Present at BIO Investment & Growth Summit
Reuters · 02/24 12:30
Soligenix Inc. Publishes 2026 Shareholder Letter
Reuters · 02/12 21:09
SOLIGENIX : CONTINUE TO EVALUATE POTENTIAL STRATEGIC OPTIONS, INCLUDING, BUT NOT LIMITED TO, PARTNERSHIP AND MERGER AND ACQUISITION OPPORTUNITIES
Reuters · 02/12 12:34
Soligenix Advances Phase 3 FLASH2 Trial for HyBryte in Cutaneous T-Cell Lymphoma
Reuters · 02/12 12:34
Soligenix Reports Progress on HyBryte Phase 3 Trial and Outlines 2026 Milestones
Reuters · 02/12 12:31
More
Webull provides a variety of real-time SNGXW stock news. You can receive the latest news about SOLIGENIX WT through multiple platforms. This information may help you make smarter investment decisions.
About SNGXW
Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing products to treat rare diseases. The Company operates through two segments: Specialized BioTherapeutics and Public Health Solutions. Specialized BioTherapeutics segments includes developing of SGX301 (synthetic hypericin) a photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL). Public Health Solutions includes RiVax to protect against exposure to ricin toxin vaccine candidate and SGX943 therapeutic candidate for antibiotic resistant and infectious disease. The Company's Development programs include innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, oral mucositis in head and neck cancer, and oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201).